FSD Pharma Inc Class B (HUGE)
Company Info
CA35954B2066
35954B206
Jun 8, 2018
Highlights
$66.67K
-$16.25
$3.50 - $24.76
$2.60
0.44%
0.11
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
HUGE
N/A
N/A
N/A
N/A
N/A
N/A
N/A
^GSPC (Benchmark)
1.00%
12.45%
0.40%
11.91%
15.05%
15.04%
10.82%
Monthly Returns
The table below presents the monthly returns of HUGE, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | -9.22% | 4.20% | -17.76% | -43.05% | -26.38% | -46.00% | -37.65% | -31.00% | -11.70% | 34.75% | -90.98% | ||
| 2023 | 35.72% | 64.49% | -11.93% | -3.87% | -28.19% | 7.48% | 1.74% | 10.26% | -6.16% | -14.09% | 0.96% | -12.40% | 16.67% |
| 2022 | -13.73% | 19.32% | -17.53% | 16.64% | -2.99% | -19.37% | 13.92% | 1.01% | -9.25% | 3.01% | -0.21% | -7.03% | -22.71% |
| 2021 | 28.85% | 2.49% | -7.28% | -5.76% | -1.67% | -1.69% | 0.57% | 4.57% | -13.66% | -12.03% | -13.67% | -15.00% | -34.62% |
| 2020 | 15.87% | -34.34% | -8.23% | -14.02% | -8.86% | 28.96% | -5.22% | -12.40% | -19.81% | -44.31% | 50.70% | -27.10% | -71.26% |
| 2019 | 24.59% | -21.16% | -15.28% | 5.62% | -18.62% | -18.30% | -28.39% | -13.64% | -10.74% | -55.59% | -21.92% | 12.86% | -87.37% |
| 2018 | 50.12% | -4.87% | 58.48% | 184.48% | -33.33% | -18.92% | -28.70% | 148.14% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of HUGE is 5, meaning it’s performing worse than 95% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for FSD Pharma Inc Class B (HUGE) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the FSD Pharma Inc Class B. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the FSD Pharma Inc Class B was 99.96%, occurring on Sep 3, 2024. The portfolio has not yet recovered.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -99.96% | Sep 24, 2018 | 1495 | Sep 3, 2024 | — | — | — |
| -33.33% | Jul 3, 2018 | 33 | Aug 17, 2018 | 8 | Aug 29, 2018 | 41 |
| -24.14% | Sep 11, 2018 | 3 | Sep 13, 2018 | 4 | Sep 19, 2018 | 7 |
| -16.22% | Jun 26, 2018 | 2 | Jun 27, 2018 | 3 | Jul 2, 2018 | 5 |
| -14.27% | Jun 11, 2018 | 4 | Jun 14, 2018 | 3 | Jun 19, 2018 | 7 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of FSD Pharma Inc Class B over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of FSD Pharma Inc Class B, comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -33.3%.
Valuation
The Valuation section provides an overview of how FSD Pharma Inc Class B is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for HUGE compared to other companies in the Drug Manufacturers - Specialty & Generic industry. HUGE currently has a PEG ratio of 0.0. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for HUGE relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, HUGE has a P/S ratio of 91.9. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for HUGE in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, HUGE has a P/B value of 0.9. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |